Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Taste Assessment of RO7017773 Formulations
NCT03847987Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alogabat in Autism Spectrum Disorder (ASD) (2 cohorts), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of RO7017773 (Part 1), Cmax of RO7017773 (Part 2) and 1 more. Started Mar 2019; status: completed.
02
Drugs
alogabat
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03847987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847987.